HSV-2 (baseline) | Unadjusted | Multivariable adjusted* | |||
---|---|---|---|---|---|
Variable | Negative (n=552) | Positive (n=63) | p Value | OR (95% CI) | p Value |
Age group: n (row %) | |||||
18–24 | 293 (88.0) | 40 (12.0) | 0.28 | 1 (ref.) | |
25–34 | 219 (91.6) | 20 (8.4) | 0.47 (0.25 to 0.91) | 0.02 | |
35+ | 40 (93.0) | 3 (7.0) | 0.29 (0.07 to 1.24) | 0.09 | |
Socioeconomic status: n (row %) | |||||
Low | 196 (87.5) | 28 (12.5) | 0.34 | 1 (ref.) | |
Medium | 235 (92.2) | 20 (7.8) | 0.63 (0.36 to 1.12) | 0.12 | |
High | 107 (88.4) | 14 (11.6) | 0.98 (0.48 to 1.98) | 0.95 | |
Unknown | 14 (93.3) | 1 (6.7) | 0.48 (0.06 to 3.99) | 0.50 | |
HIV-1: n (row %) | |||||
Negative | 357 (92.7) | 28 (7.3) | 0.00 | 1 (ref.) | |
Positive | 195 (84.8) | 35 (15.2) | 2.46 (1.43 to 4.21) | 0.00 | |
Neisseria gonorrhoeae, n (row %) | |||||
Negative | 511 (89.8) | 58 (10.2) | 0.60 | 1 (ref.) | |
Positive | 34 (87.2) | 5 (12.8) | 1.02 (0.37 to 2.81) | 0.97 | |
Trichomonas vaginalis, n (row %) | |||||
Negative | 464 (89.7) | 53 (10.3) | 0.83 | 1 (ref.) | |
Positive | 81 (89.0) | 10 (11.0) | 0.93 (0.44 to 1.96) | 0.85 | |
Chlamydia trachomatis, n (row %) | |||||
Negative | 443 (89.7) | 51 (10.3) | 0.97 | 1 (ref.) | |
Positive | 103 (89.6) | 12 (10.4) | 0.92 (0.46 to 1.84) | 0.81 | |
Gravidity: median (IQR) | 2 (1–2) | 2 (1–3) | 0.62 | 1.26 (0.95 to 1.66) | 0.11 |
Clinical: n (%) | |||||
Asymptomatic | 363 (90.3) | 39 (9.7) | 0.53 | 1 (ref.) | |
Symptomatic | 188 (88.7) | 24 (11.3) | 0.99 (0.57 to 1.74) | 0.98 |
*Adjusted for socioeconomic status, gravidity, chlamydia, trichomonas and gonorrhoea.
HSV-2, herpes simplex virus-2.